Latest news

• J&J’s ponesimiod tops Aubagio in head-to-head MS trial

  Sets up regulatory filings and possible approval next year. Johnson &Johnson’s oral multiple sclerosis (MS) therapy ponesimod outperformed Sanofi blockbuster Aubagio in a phase 3 comparative trial, setting up regulatory ... Ponesimod, a S1P receptor

• J&J agrees $30bn deal to acquire Actelion

  J&J also takes control of Actelion's late-stage pipeline, including multiple sclerosis candidate ponesimod and cadazolid for diarrhoeal disease, and the US group has also taken an option on

• J&J back in frame to buy Actelion after Sanofi talks break down

  The two new drugs are predicted to bring in combined sales of $4bn-plus by 2020, and Actelion also has some pipeline candidates in which Clozel has great confidence -including ponesimod

• Resurgent Actelion catches J&J's eye

  J&J could also provide resources to bring forward Actelion's well-regarded pipeline of drugs that extends outside its core focus of PAH, including multiple sclerosis candidate ponesimod and cadazolid